13 results about "Glaucoma" patented technology

A glaucoma drainage tube and its manufacturing process are disclosed, relating to the field of ophthalmic medical device technology. The tube is manufactured using a drainage tube manufacturing device, which includes a negative electrode, a positive electrode, and a power source. The negative electrode comprises a middle section and a terminal section, with the outer surface of the terminal section being trumpet-shaped. The negative electrode consists of two interlocking parts. The distance between the central axis of the middle section and the positive electrode is 0.3–2 cm. The positive and negative terminals of the power source are connected to the negative and positive electrodes, respectively. The manufacturing process includes the following steps: providing an acidic electrolyte; placing the working electrode and the positive electrode in the electrolyte for an electrochemical reaction to form a collagen film on the circumferential surface of the working electrode, obtaining a preliminary product; cross-linking the preliminary product; and then extracting the two parts of the negative electrode from within the collagen film towards the terminal section, respectively, to obtain the glaucoma drainage tube. This method can produce a glaucoma drainage tube with trumpet-shaped ends, improving the problem of easy displacement of existing glaucoma drainage tubes after implantation into the eye.

This invention discloses an injectable hydrogel for long-term sustained release of NGF and CNTF, its preparation method, and its application in visual system diseases. The bioactive factor sustained-release hydrogel of this invention comprises a hydrogel matrix and bioactive factor microspheres loaded on the matrix; the raw materials for preparing the hydrogel matrix include chitosan, type II collagen, and hyaluronic acid; the bioactive factor microspheres comprise an inner core and a capsule wall, the inner core being a bioactive factor selected from one or both of ciliary neurotrophic factor and nerve growth factor, and the capsule wall being a polylactic acid-glycolic acid copolymer. This hydrogel can achieve long-term stable release of NTF, activating endogenous neural stem cells in the retina to generate new retinal ganglion cells. It exhibits high safety, good injectability, and a long sustained-release period, and can be used to prepare drugs for treating visual system diseases such as glaucoma, optic nerve damage, and macular degeneration.

A system may include a headset device and an average hill of vision model (HoV) and may generate an eye difference estimate relative to reference data for an average healthy eye obtained from a normative dataset. The eye difference estimate indicates a difference in overall sensitivity or general height and the rate of sensitivity decay with eccentricity relative to the reference data. The system may generate an individualized HoV model based on the eye difference estimate and the average HoV model, display, on the headset device, a respective stimulus at a plurality of test locations, store responses to the stimulus, and analyze the responses to determine a respective sensitivity value at each of the plurality of test locations. The system may determine total-deviation values by subtracting the respective sensitivity value from a corresponding value of the individualized HoV model, analyze the total-deviation values, and provide feedback based on the analysis.

This invention discloses the application of bimatoprost in the preparation of drugs for the prevention and / or treatment of Parkinson's disease, within the field of drug reuse. Bimatoprost is a prostaglandin F2α analog, currently mainly used for glaucoma and eyelash growth. This invention has found that bimatoprost can improve Parkinson's disease-related behavioral disorders, increase the expression of tyrosine hydroxylase, a protein associated with dopaminergic neurons in the substantia nigra, and reduce the abnormal accumulation of α-synuclein, thus exhibiting good ameliorative and protective effects against Parkinson's disease. This invention provides a new drug option for the treatment of Parkinson's disease.

A system may include a headset device comprising a display screen and an adaptive map perimetry algorithm that is configured to access or implement a normative database or model. The system may implement a VF test adapted to fit an area of the display screen based on values in the normative database or model and is rendered as a same or similar visualization compared to one or more different headset devices having different display screens having different respective shapes, formats, sizes, and / or resolutions. The system may receive visual test data indicating a visual field of the user and detect one or more initial test locations. The one or more initial test locations define one or more healthy clusters indicative of an absence of scatoma and one or more damaged clusters indicative of scotoma. The system may generate a spatial mapping identifying locations of the one or more damaged clusters.

The application provides an application of YAP in preparation of a drug for preventing or treating retinal ganglion cell injury, and proves that up-regulation of YAP expression or activity can significantly reduce the retinal oxidative stress level, inhibit the neuroinflammatory response, and reduce the number of RGC death, thereby effectively protecting the nerve function. The application provides a new treatment target for diseases characterized by RGC injury, such as traumatic optic neuropathy and glaucoma, and YAP or an expression promoter thereof can be used for preparing a drug for preventing, relieving and / or treating the diseases, and has an important clinical application prospect.

The present disclosure provides an ophthalmic formulation comprising one or more pharmaceutically acceptable excipients; a pharmaceutically active compound that is capable of reducing the amount or deleterious actions of autoantibodies on the ocular surface, such as IgG; In particular, the present disclosure provides an ophthalmic formulation where the pharmaceutically active compound is capable of treating a clinical condition selected from the group consisting of inflammatory, infectious and immunological ocular surface or intraocular disease that can cause symptoms of ocular discomfort, keratitis, dry eye disease, symblepheron formation, fornix foreshortening, eyelid margin / conjunctival keratinization, subconjunctival fibrosis, retinal gliosis and glaucoma.

A medical device for generating a fluid channel in an eye tissue layer is disclosed, addressing limitations of conventional glaucoma treatments such as variable channel formation, collateral tissue da

This invention provides a frame-type upconversion infrared visualization glasses, its fabrication method, and its applications, relating to the fields of infrared visualization materials and wearable optical devices. The optical lens of the glasses comprises, from the incident side to the wearer side, an infrared anti-reflection layer, an upconversion core-shell luminescent layer, a visible light gain layer, an infrared reflective layer, and a protective eye layer. This invention uses mesoporous SiO2 nanospheres as the core to construct the upconversion core-shell luminescent layer, and combines it with the infrared anti-reflection layer, visible light gain layer, infrared reflective layer, and protective eye layer to form a five-layer optical enhancement structure. This structure is integrated into the frame lens using a layer-by-layer injection molding and graded curing process, achieving multiple recycling of near-infrared light, efficient loading of rare-earth luminescent components, a significant improvement in upconversion luminescence efficiency, and a synergistic enhancement of visible light output brightness and uniformity on the wearer side. It has broad application prospects in the field of visual assistance for patients with retinitis pigmentosa and late-stage glaucoma.

A system may include a headset device comprising a display screen positioned proximate to, or within a viewable distance from a user's eyes. The headset device may be communicatively coupled to one or more processors. The system may cause the one or more processors to display a stimulus to a test subject (e.g., a patient), store in computer memory a response of the test subject to the displayed stimulus, analyze the response based on a location of the displayed stimulus, and provide feedback to the test subject based on the response and analysis.

This invention discloses a method and device for glaucoma diagnosis and progression prediction based on deep multimodal fusion and collaborative attention mechanisms, belonging to the field of medical artificial intelligence and computer-aided diagnostic technology. This invention acquires multimodal data including clinical text, fundus images, and optical coherence tomography (OCT) scans; for low-quality fundus images, it employs an algorithm that fuses nonlocal denoising and contrast-constrained histogram equalization to enhance image quality; it constructs independent feature extractors to obtain clinical text features, enhanced fundus image features, and OCT features; it effectively fuses multimodal features through a dual-gate residual attention module and a dual-spectrum cross-attention module; finally, based on a gated attention module, it uses the fused features to diagnose glaucoma and predict disease progression. This method fully utilizes the complementarity between multimodal information and effectively processes low-quality images, significantly improving the accuracy of glaucoma diagnosis and the performance of progression prediction.

The application discloses an eye drug delivery hydrogel system based on dynamic chemical cross-linking and a preparation method and application thereof. The preparation is simple, has excellent self-healing, injectable, adhesive and sustained-release characteristics, can significantly improve the bioavailability of eye drugs, and has a wide application prospect in the treatment of eye diseases such as dry eye, glaucoma and keratitis.